These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 3280699)

  • 1. Absence of specific histologic changes in guinea pig skin treated with bullous pemphigoid antibodies.
    Gammon WR; Briggaman RA
    J Invest Dermatol; 1988 Apr; 90(4):495-500. PubMed ID: 3280699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental bullous pemphigoid in guinea pigs: the role of pemphigoid antibodies, complement, and migrating cells.
    Naito K; Morioka S; Ikeda S; Ogawa H
    J Invest Dermatol; 1984 Mar; 82(3):227-30. PubMed ID: 6366073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predominance of IgG4 in prodromal bullous pemphigoid.
    Lamb PM; Patton T; Deng JS
    Int J Dermatol; 2008 Feb; 47(2):150-3. PubMed ID: 18211485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deposition of the membrane attack complex of complement in bullous pemphigoid.
    Dahl MV; Falk RJ; Carpenter R; Michael AF
    J Invest Dermatol; 1984 Feb; 82(2):132-5. PubMed ID: 6363566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of IgG subclasses and complement binding activity of autoantibodies from patients with bullous pemphigoid and pemphigus.
    Brooks WS; Lee YY; Abell E; Deng JS
    J Clin Lab Anal; 1989; 3(5):307-11. PubMed ID: 2681622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bullous pemphigoid and antinuclear antibodies. Unmasking of basement membrane fluorescence in sodium chloride-treated substrates.
    Danno K; Okamoto H; Miyauchi H; Imamura S
    Arch Dermatol; 1982 Jan; 118(1):37-9. PubMed ID: 7036909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bullous pemphigoid: a correlative study of autoantibodies, circulating immune complexes and dermo-epidermal deposits.
    Gomes MA; Dambuyant C; Thivolet J; Bussy R
    Br J Dermatol; 1982 Jul; 107(1):43-51. PubMed ID: 6809029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods.
    Gammon WR; Inman AO; Wheeler CE
    J Invest Dermatol; 1984 Jul; 83(1):57-61. PubMed ID: 6376640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional evidence for complement-activating immune complexes in the skin of patients with bullous pemphigoid.
    Gammon WR; Merritt CC; Lewis DM; Sams WM; Wheeler CE; Carlo JR
    J Invest Dermatol; 1982 Jan; 78(1):52-7. PubMed ID: 7033396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A child with antibodies targeting both linear IgA bullous dermatosis and bullous pemphigoid antigens.
    Darling TN; Cardenas AA; Beard JS; Sau P; Yee CL; Zone JJ; Yancey KB
    Arch Dermatol; 1995 Dec; 131(12):1438-42. PubMed ID: 7492135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin.
    Gammon WR; Briggaman RA; Inman AO; Queen LL; Wheeler CE
    J Invest Dermatol; 1984 Feb; 82(2):139-44. PubMed ID: 6363567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of leukocyte adherence at the basement membrane zone with subsequent activation of their metabolic pathway by pemphigoid antibodies and complement.
    Iwatsuki K; Tagami H; Yamada M
    Acta Derm Venereol; 1983; 63(4):290-5. PubMed ID: 6195859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemphigoid antibody mediated attachment of peripheral blood leukocytes at the dermal-epidermal junction of human skin.
    Gammon WR; Lewis DM; Carlo JR; Sams WM; Wheeler CE
    J Invest Dermatol; 1980 Oct; 75(4):334-9. PubMed ID: 7000926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of serum anti-basement membrane zone antibody and malignancy in bullous pemphigoid.
    Ahmed AR; Amerian ML
    Dermatologica; 1985; 171(2):82-5. PubMed ID: 3899759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complement fixing ability of anti-basement membrane zone IgG subclass of herpes gestationis and bullous pemphigoid.
    Suzuki M; Watanabe C; Yaoita H
    Acta Derm Venereol; 1989; 69(1):6-11. PubMed ID: 2563610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathogenic mechanisms of blister formation in bullous pemphigoid.
    Naito K; Morioka S; Ogawa H
    J Invest Dermatol; 1982 Nov; 79(5):303-6. PubMed ID: 6752292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid and dermatitis herpetiformis: mixed bullous disease or coexistence of two separate entities?
    Sander HM; Utz MM; Peters MS
    J Cutan Pathol; 1989 Dec; 16(6):370-4. PubMed ID: 2693505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them.
    Sugi T; Hashimoto T; Hibi T; Nishikawa T
    J Clin Invest; 1989 Oct; 84(4):1050-5. PubMed ID: 2551921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicular pemphigoid vs dermatitis herpetiformis.
    Jawitz J; Kumar V; Nigra TP; Beutner EH
    J Am Acad Dermatol; 1984 May; 10(5 Pt 2):892-6. PubMed ID: 6373860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, histological and immunological studies in 50 patients with bullous pemphigoid.
    Hadi SM; Barnetson RS; Gawkrodger DJ; Saxena U; Bird P; Merrett TG
    Dermatologica; 1988; 176(1):6-17. PubMed ID: 3276569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.